Personalis, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Christopher Hall
- Full Time Employees
- 260
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 6600 Dumbarton Circle Fremont CA United States of America 94555
- IPO Date
- Jun 20, 2019
- CIK
- 0001527753
- Website
- personalis.com
- Similar Companies
- Business
- Personalis, Inc. Personalis, Inc. (Nasdaq:PSNL) develops, markets and sells advanced cancer genomic tests and services to pharmaceutical, biopharmaceutical, diagnostics companies, universities, non-profits, government entities and patients in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for minimal residual disease detection, therapy response and recurrence monitoring in solid tumor cancers; ImmunoID NeXT, a tissue-based service combining whole exome and whole transcriptome sequencing with advanced analytics for multi-dimensional tumor and microenvironment analysis; NeXT Personal Dx and NeXT Dx for MRD detection and tumor profiling to guide therapy selection and clinical trials; whole exome and genome sequencing services for diagnostic inputs and population research initiatives; as well as proprietary ACE Technology for enhanced sequencing accuracy across difficult genomic regions. Personalis serves the precision oncology sector, focusing on biomarker discovery, personalized cancer immunotherapies, neoantigen prediction and translational research to support drug development and clinical trials. Founded in 2011 and headquartered in Fremont, California, the company recently expanded its collaboration with Tempus AI, Inc. through a $36 million equity investment in 2024 to accelerate commercialization of ultra-sensitive MRD testing for colorectal cancer; received a $50 million investment from Merck in December 2024, resulting in approximately 16.5% ownership, alongside a multi-year extension of its partnership with Moderna for the ImmunoID NeXT Platform in the V940/mRNA-4157 individualized neoantigen therapy program; and plans reimbursement submissions for NeXT Personal products to CMS in late 2024 or early 2025.
Company News
Personalis, Inc. (NASDAQ:PSNL) Given Consensus Recommendation of “Hold” by Brokerages
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
Personalis Reports Second Quarter Results and Recent Highlights
PSNL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Personalis to Tempus AI
Are BOW, UTZ, PSNL Obtaining Fair Deals for their Shareholders?
PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus
Halper Sadeh LLC is Investigating Whether FNWD and PSNL are Obtaining Fair Deals for their Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—LXP, DMAA, PSNL, and FNWD
Are FNWD, PSNL, DSGR Obtaining Fair Deals for their Shareholders?
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Luxfer Holdings PLC (NYSE – LXFR), Finward Bancorp (Nasdaq – FNWD), Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR)
Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL
Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders?
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Personalis, Inc. (NASDAQ: PSNL)
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)
Personalis, Inc. (PSNL) M&A Call Transcript
PSNL Stock Alert: Halper Sadeh LLC is Investigating Whether Personalis, Inc. is Obtaining a Fair Price for Shareholders
Tempus AI Bets on MRD Testing Growth With Personalis Acquisition
Shareholder Alert: Ademi LLP investigates whether Personalis, Inc. is obtaining a Fair Price for Public Shareholders
PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus
Shareholder Alert: Ademi LLP investigates whether Personalis, Inc. is obtaining a Fair Price for Public Shareholders